Caprius Announces Successful Launch of Aurora JointVenture At Englewood Hospital and Medical...

WILMINGTON, Mass.--(BUSINESS WIRE)--Oct. 22, 1998--Caprius, Inc. (Nasdaq: CAPR) announced today the successful launch of its Aurora(R) system at Englewood Hospital and Medical Center.

The Aurora(R) system has been operating for approximately one month and is experiencing robust patient

throughput. In addition, the Medical Center has been receiving reimbursement for procedures that management believes will result in significant revenues for Caprius. The recent grand opening of Caprius' first joint venture in the New York metropolitan area was widely publicized and highlighted in news media and print.

"The increased indications for breast MR (magnetic resonance) has attracted women to our Center from a wide geographic web. As the fourth site in the world to enjoy the benefits of the Aurora(R) system, we are participating in the growing data supporting the clinical advantages and benefits of MR breast imaging with the Aurora(R) system," stated Miguel A. Sanchez, M.D., Medical Director of The Breast Care Center at Englewood Hospital and Medical Center.

Commenting on the opening, Jack Nelson, Chairman and CEO, stated, "We are extremely encouraged, not only by the significant publicity generated, but also from the early results which combined with the success of our installation at the Faulkner-Sagoff Centre for Breast Healthcare in Boston should increase awareness of the clinical and financial benefits of breast MRI."

Caprius, Inc. is dedicated to the development and commercialization of the Aurora system, a breast imaging system based on magnetic resonance imaging (MRI). The Aurora is the only FDA-cleared, MRI-based dedicated breast imaging system in the United States.

Safe Harbor Statement:

The statements made in this press release that are not historical fact are "forward-looking statements" which are based upon current expectations that include a number of risks and uncertainties. Factors that could cause actual results to differ materially from the forward-looking statements include meeting ordinary and customary closing conditions, delays in product development, lack of market acceptance of technology, technological innovations of competitors and changes in health care regulations, including reimbursement programs.